Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ENOV NASDAQ:IRMD NASDAQ:SLNO NASDAQ:TMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENOVEnovis$26.29-14.8%$32.61$26.29▼$49.83$1.76B1.7931,250 shs3.97 million shsIRMDiRadimed$56.69-1.3%$57.62$42.34▼$63.29$730.48M0.9144,061 shs30,893 shsSLNOSoleno Therapeutics$87.20-0.5%$79.60$41.50▼$90.32$4.42B-2.63853,684 shs1.19 million shsTMDXTransMedics Group$109.88-2.3%$127.16$55.00▼$177.37$3.81B2.061.38 million shs789,501 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENOVEnovis+0.88%-14.40%-0.48%-3.60%-35.09%IRMDiRadimed-0.79%-3.40%-0.91%+10.97%+24.40%SLNOSoleno Therapeutics+2.48%+9.11%+12.94%+25.24%+80.03%TMDXTransMedics Group-0.71%-9.83%-17.39%+27.52%-24.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENOVEnovis2.7084 of 5 stars3.41.00.00.02.11.71.9IRMDiRadimed4.9252 of 5 stars3.53.02.54.42.73.31.9SLNOSoleno Therapeutics4.1852 of 5 stars3.51.00.04.62.72.50.6TMDXTransMedics Group2.0898 of 5 stars2.41.00.00.02.22.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENOVEnovis 2.80Moderate Buy$55.60111.49% UpsideIRMDiRadimed 3.00Buy$72.0027.01% UpsideSLNOSoleno Therapeutics 3.09Buy$108.7024.66% UpsideTMDXTransMedics Group 2.89Moderate Buy$129.8818.20% UpsideCurrent Analyst Ratings BreakdownLatest IRMD, TMDX, SLNO, and ENOV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025TMDXTransMedics GroupCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$129.00 ➝ $142.007/11/2025SLNOSoleno TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$105.00 ➝ $121.007/8/2025ENOVEnovisEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$48.00 ➝ $46.006/23/2025SLNOSoleno TherapeuticsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy6/23/2025SLNOSoleno TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$110.006/17/2025TMDXTransMedics GroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$130.00 ➝ $150.006/17/2025TMDXTransMedics GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold6/4/2025TMDXTransMedics GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$125.00 ➝ $145.006/3/2025TMDXTransMedics GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/14/2025ENOVEnovisCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $70.005/9/2025ENOVEnovisJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$62.00 ➝ $55.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENOVEnovis$2.11B0.71$16.33 per share1.61$45.10 per share0.58IRMDiRadimed$73.24M9.85$1.56 per share36.31$6.85 per share8.28SLNOSoleno TherapeuticsN/AN/AN/AN/A$5.68 per shareN/ATMDXTransMedics Group$441.54M8.42$1.61 per share68.39$6.81 per share16.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENOVEnovis-$825.49M-$13.959.838.24N/A-37.65%5.99%3.44%8/7/2025 (Estimated)IRMDiRadimed$19.23M$1.5536.5728.35N/A26.33%23.28%20.59%7/30/2025 (Estimated)SLNOSoleno Therapeutics-$175.85M-$4.62N/AN/AN/AN/A-77.52%-63.44%8/6/2025 (Estimated)TMDXTransMedics Group$35.46M$1.3680.7976.84N/A10.03%21.88%6.15%7/30/2025 (Estimated)Latest IRMD, TMDX, SLNO, and ENOV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ENOVEnovis$0.74N/AN/AN/A$555.80 millionN/A8/7/2025Q2 2025IRMDiRadimed$0.45N/AN/AN/AN/AN/A8/6/2025Q2 2025SLNOSoleno Therapeutics-$0.85N/AN/AN/A$3.91 millionN/A7/30/2025Q2 2025TMDXTransMedics Group$0.48N/AN/AN/A$146.64 millionN/A5/8/2025Q1 2025ENOVEnovis$0.74$0.81+$0.07-$0.98$558.80 million$558.83 million5/8/2025Q1 2025TMDXTransMedics Group$0.29$0.70+$0.41$0.70$123.39 million$143.54 million5/7/2025Q1 2025SLNOSoleno Therapeutics-$1.14-$0.95+$0.19-$0.95N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENOVEnovisN/AN/AN/AN/AN/AIRMDiRadimed$0.681.20%N/A43.87%1 YearsSLNOSoleno TherapeuticsN/AN/AN/AN/AN/ATMDXTransMedics GroupN/AN/AN/AN/AN/ALatest IRMD, TMDX, SLNO, and ENOV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025IRMDiRadimedquarterly$0.171.3%5/20/20255/20/20255/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENOVEnovis0.522.551.32IRMDiRadimedN/A8.877.62SLNOSoleno Therapeutics0.2119.6419.64TMDXTransMedics Group1.929.108.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENOVEnovis98.45%IRMDiRadimed92.34%SLNOSoleno Therapeutics97.42%TMDXTransMedics Group99.67%Insider OwnershipCompanyInsider OwnershipENOVEnovis2.70%IRMDiRadimed36.80%SLNOSoleno Therapeutics6.40%TMDXTransMedics Group7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENOVEnovis7,36757.12 million55.58 millionOptionableIRMDiRadimed11012.72 million8.04 millionOptionableSLNOSoleno Therapeutics3050.39 million47.17 millionOptionableTMDXTransMedics Group21033.82 million31.46 millionOptionableIRMD, TMDX, SLNO, and ENOV HeadlinesRecent News About These CompaniesCanaccord Genuity Group Issues Positive Forecast for TransMedics Group (NASDAQ:TMDX) Stock PriceJuly 18 at 4:05 AM | americanbankingnews.comTransMedics to Report Second Quarter 2025 Financial Results on July 30, 2025July 16 at 4:19 PM | prnewswire.comTransMedics Group (NASDAQ:TMDX) Given New $142.00 Price Target at Canaccord Genuity GroupJuly 15 at 1:39 PM | marketbeat.comTransMedics: Q2 Analyst Estimates Will Fall ShortJuly 14, 2025 | seekingalpha.comEmerald Advisers LLC Boosts Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)July 13, 2025 | marketbeat.comPrincipal Financial Group Inc. Buys 5,480 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)July 13, 2025 | marketbeat.comWhat is William Blair's Estimate for TMDX Q1 Earnings?July 13, 2025 | americanbankingnews.comEmerald Mutual Fund Advisers Trust Grows Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)July 12, 2025 | marketbeat.comTransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Rating of "Moderate Buy" by AnalystsJuly 12, 2025 | americanbankingnews.comTransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Rating of "Moderate Buy" from AnalystsJuly 12, 2025 | marketbeat.comTransMedics Group (NASDAQ:TMDX) Stock Price Down 5.2% - What's Next?July 11, 2025 | marketbeat.comBrokers Issue Forecasts for TMDX Q1 EarningsJuly 11, 2025 | marketbeat.comTransMedics Group, Inc. (NASDAQ:TMDX) Stake Boosted by OneDigital Investment Advisors LLCJuly 11, 2025 | marketbeat.comNew York State Teachers Retirement System Acquires 14,200 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)July 10, 2025 | marketbeat.comVontobel Holding Ltd. Makes New $291,000 Investment in TransMedics Group, Inc. (NASDAQ:TMDX)July 9, 2025 | marketbeat.comTransMedics Group, Inc. (NASDAQ:TMDX) Shares Purchased by Cambridge Investment Research Advisors Inc.July 7, 2025 | marketbeat.comTMDX - TransMedics Group Inc Executives - MorningstarJuly 5, 2025 | morningstar.comMTransMedics Group, Inc. (TMDX) Cash Flow - Yahoo FinanceJuly 4, 2025 | finance.yahoo.comIs TransMedics Stock a Buy After Short-Seller Drama?July 3, 2025 | fool.comTMDX - TransMedics Group Inc Key Metrics - MorningstarJuly 3, 2025 | morningstar.comMJanney Montgomery Scott LLC Has $592,000 Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)July 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIRMD, TMDX, SLNO, and ENOV Company DescriptionsEnovis NYSE:ENOV$26.29 -4.57 (-14.81%) Closing price 03:59 PM EasternExtended Trading$26.46 +0.16 (+0.63%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.iRadimed NASDAQ:IRMD$56.69 -0.76 (-1.32%) Closing price 04:00 PM EasternExtended Trading$56.52 -0.16 (-0.29%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.Soleno Therapeutics NASDAQ:SLNO$87.20 -0.44 (-0.50%) Closing price 04:00 PM EasternExtended Trading$87.16 -0.05 (-0.05%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.TransMedics Group NASDAQ:TMDX$109.88 -2.64 (-2.35%) Closing price 04:00 PM EasternExtended Trading$110.54 +0.66 (+0.60%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
